Kang, S. P., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., & Rubin, E. H. (2017). Pembrolizumab KEYNOTE-001: An adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol.

Kang, S. P., K. Gergich, G. M. Lubiniecki, D. P. de Alwis, C. Chen, M. A. B. Tice, och E. H. Rubin. "Pembrolizumab KEYNOTE-001: An Adaptive Study Leading to Accelerated Approval for Two Indications and a Companion Diagnostic." Ann Oncol 2017.

Kang, S. P., et al. "Pembrolizumab KEYNOTE-001: An Adaptive Study Leading to Accelerated Approval for Two Indications and a Companion Diagnostic." Ann Oncol 2017.